Immune modulation of effector CD4+ and regulatory T cell function by sorafenib in patients with hepatocellular carcinoma

Liver Transplantation for Hepatocellular Carcinoma: Five Steps to Prevent Recurrence

(2011) C. Toso et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Increased Frequency of CD4+CD25highFoxP3+ Regulatory T Cells in Patients with Hepatocellular Carcinoma

(2011) Xi Feng et al.   ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS

Increased prevalence of regulatory T cells in the lung cancer microenvironment: a role of thymic stromal lymphopoietin

(2011) Hui Li et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Immunomodulatory effects of sorafenib on peripheral immune effector cells in metastatic renal cell carcinoma

(2011) Antonia Busse et al.   EUROPEAN JOURNAL OF CANCER

Targeted Therapies for Hepatocellular Carcinoma

(2011) Augusto Villanueva et al.   GASTROENTEROLOGY

Field-practice study of sorafenib therapy for hepatocellular carcinoma: A prospective multicenter study in Italy

(2011) Massimo Iavarone et al.   HEPATOLOGY

Kinase inhibitor Sorafenib modulates immunosuppressive cell populations in a murine liver cancer model

(2011) Mengde Cao et al.   LABORATORY INVESTIGATION

Cancer Statistics, 2010

(2010) A. Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

High-performance liquid chromatographic method for the determination of sorafenib in human serum and peritoneal fluid

(2010) Werner J. Heinz et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

IL-2-deprivation and TGF-β are two non-redundant suppressor mechanisms of CD4+CD25+ regulatory T cell which jointly restrain CD4+CD25− cell activation

(2010) Guohua Wang et al.   IMMUNOLOGY LETTERS

Design and rationale for the non-interventional Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib (GIDEON) study

(2010) R. Lencioni et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Single-cell quantification of IL-2 response by effector and regulatory T cells reveals critical plasticity in immune response

(2010) Ofer Feinerman et al.   Molecular Systems Biology

Influence of Serum and Soluble CD25 (sCD25) on Regulatory and Effector T-cell Function in Hepatocellular Carcinoma

(2010) R. Cabrera et al.   SCANDINAVIAN JOURNAL OF IMMUNOLOGY

Hepatocellular Carcinoma Immunopathogenesis: Clinical Evidence for Global T Cell Defects and an Immunomodulatory Role for Soluble CD25 (sCD25)

(2009) Roniel Cabrera et al.   DIGESTIVE DISEASES AND SCIENCES

Mechanisms of Foxp3+ T Regulatory Cell-Mediated Suppression

(2009) Ethan M. Shevach   IMMUNITY

Increased intratumoral regulatory T cells are related to intratumoral macrophages and poor prognosis in hepatocellular carcinoma patients

(2009) Jia Zhou et al.   INTERNATIONAL JOURNAL OF CANCER

The Kinase Inhibitors Sunitinib and Sorafenib Differentially Affect NK Cell Antitumor Reactivity In Vitro

(2009) M. Krusch et al.   JOURNAL OF IMMUNOLOGY

Validation of an HPLC-UV method for sorafenib determination in human plasma and application to cancer patients in routine clinical practice

(2009) B. Blanchet et al.   JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

MAPK-independent impairment of T-cell responses by the multikinase inhibitor sorafenib

(2009) R. Houben et al.   MOLECULAR CANCER THERAPEUTICS

Influence of Membrane CD25 Stability on T Lymphocyte Activity: Implications for Immunoregulation

(2009) Todd M. Brusko et al.   PLoS One

Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses

(2008) M. M. Hipp et al.   BLOOD

Diagnosis and Treatment of Hepatocellular Carcinoma

(2008) Hashem B. El-Serag et al.   GASTROENTEROLOGY

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

(2008) Ann-Lii Cheng et al.   LANCET ONCOLOGY

Sorafenib inhibits activation of human peripheral blood T cells by targeting LCK phosphorylation

(2008) W Zhao et al.   LEUKEMIA

Sorafenib in Advanced Hepatocellular Carcinoma

(2008) Josep M. Llovet et al.   NEW ENGLAND JOURNAL OF MEDICINE